Insider Selling: Fractyl Health, Inc. (NASDAQ:GUTS) Insider Sells 22,346 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 22,346 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.81, for a total transaction of $40,446.26. Following the sale, the insider now directly owns 153,544 shares of the company’s stock, valued at approximately $277,914.64. The trade was a 12.70 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jay David Caplan also recently made the following trade(s):

• On Monday, November 11th, Jay David Caplan sold 64,197 shares of Fractyl Health stock. The stock was sold at an average price of $2.47, for a total value of $158,566.59.

Fractyl Health Price Performance

Shares of NASDAQ GUTS traded down $0.14 during trading on Monday, reaching $1.70. The company had a trading volume of 583,333 shares, compared to its average volume of 409,278. Fractyl Health, Inc. has a 52 week low of $1.68 and a 52 week high of $13.99. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The business’s 50 day moving average price is $2.06 and its 200-day moving average price is $2.51. The stock has a market cap of $81.77 million and a PE ratio of -0.14.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.02. The company had revenue of $0.01 million during the quarter. Analysts expect that Fractyl Health, Inc. will post -1.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley reduced their price objective on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research note on Monday.

Hedge Funds Weigh In On Fractyl Health

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in Fractyl Health by 166.5% during the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock worth $1,269,000 after purchasing an additional 313,335 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock worth $53,000 after buying an additional 7,397 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Fractyl Health by 56.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after buying an additional 29,262 shares during the period. Barclays PLC boosted its stake in Fractyl Health by 1,754.7% in the third quarter. Barclays PLC now owns 47,796 shares of the company’s stock valued at $121,000 after acquiring an additional 45,219 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Fractyl Health during the 3rd quarter worth $33,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.